Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets

Nature Communications

Volumn 8, Issue , 2017, Pages

  Chen, Bin ^a   Ma, Li ^b   Paik, Hyojung ^a,c   Sirota, Marina ^a   Wei, Wei ^b   Chua, Mei Sze ^b   So, Samuel ^b   Butte, Atul J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Korea Institute of Science and Technology Information (KISTI)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PYRVINIUM EMBONATE; ANTINEOPLASTIC AGENT;

CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; DRUG; GENE EXPRESSION; GENOMICS; MOLECULAR ANALYSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; GENE EXPRESSION; IN VIVO STUDY; LIVER CANCER; LIVER CANCER CELL LINE; MOUSE; NONHUMAN; TUMOR GENE; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECT; DRUG SCREENING; HEP-G2 CELL LINE; HUMAN; LIVER TUMOR; METABOLISM; NUDE MOUSE; SYSTEMS BIOLOGY; VALIDATION STUDY;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; GENE EXPRESSION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; PYRVINIUM COMPOUNDS; SYSTEMS BIOLOGY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85024090378     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms16022     Document Type: Article

References (63)

1. Hoadley, K. A., et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929-944 (2014
2. Mertins, P., et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 (2016
3. Hakimi, A. A., et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29, 104-116 (2016
4. Zhang, H., et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 166, 755-765 (2016
5. Chen, B., & Butte, A. J. Leveraging big data to transform target selection and drug discovery. Clin. Pharmacol. Ther. 99, 285-297 (2015
6. Wilmes, A., et al. Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J. Proteomics 79, 180-194 (2013
7. Abelin, J. G., et al. Reduced-representation phosphosignatures measured by quantitative targeted MS capture cellular states and enable large-scale comparison of drug-induced phenotypes. Mol. Cell. Proteomics 15, 1622-1641 (2016
8. Lamb, J., et al. The connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006
9. LINCS. NIH LINCS Program. Available at http://www.lincsproject.org
10. Jahchan, N. S., et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 3, 1364-1377 (2013
11. van Noort, V., et al. Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling. Cancer Res. 74, 5690-5699 (2014
12. Sirota, M., et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011
13. Pessetto, Z. Y., et al. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. Oncotarget 8, 4079-4095 (2016
14. Zerbini, L. F., et al. Computational repositioning and preclinical validation of pentamidine for renal cell cancer. Molecular cancer therapeutics 13, 1929-1941 (2014
15. Dudley, J. T., et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 3, 96ra76 (2011
16. Brum, A. M., et al. Connectivity map-based discovery of parbendazole reveals targetable human osteogenic pathway. Proc. Natl Acad. Sci. USA 112, 12711-12716 (2015
17. Cheng, J., Yang, L., Kumar, V., & Agarwal, P. Systematic evaluation of connectivity map for disease indications. Genome Med. 6, 540 (2014
18. Wagner, A., et al. Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia. Mol. Syst. Biol. 11, 791 (2015
19. Gaulton, A., et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-D1107 (2012
20. Barretina, J., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012
21. TCGA. The Cancer Genome Atlas. Available at https://tcga-data.nci.nih.gov
22. Haibe-Kains, B., et al. Inconsistency in large pharmacogenomic studies. Nature 504, 389-393 (2013
23. Fallahi-Sichani, M., Honarnejad, S., Heiser, L. M., Gray, J. W., & Sorger, P. K. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat. Chem.l Biol. 9, 708-714 (2013
24. Seashore-Ludlow, B., et al. Harnessing connectivity in a large-scale smallmolecule sensitivity dataset. Cancer Discov. 5, 1210-1223 (2015
25. Hafner, M., Niepel, M., Chung, M., & Sorger, P. K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13, 521-527 (2016
26. Demontis, G. C., Ratto, G. M., Bisti, S., & Cervetto, L. Effect of blocking the Na+/K+ ATPase on Ca2+ extrusion and light adaptation in mammalian retinal rods. Biophys. J. 69, 439-450 (1995
27. Park, K. S., et al. FCCP depolarizes plasma membrane potential by activating proton and Na+ currents in bovine aortic endothelial cells. Pflugers Arch.y 443, 344-352 (2002
28. Alao, J. P., & Sunnerhagen, P. The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation. Radiat. Oncol. 4, 51 (2009
29. Thorne, C. A., et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat. Chem. Biol. 6, 829-836 (2010
30. Xu, W., et al. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS ONE 8, e71508 (2013
31. Pez, F., et al. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J. Hepatol. 59, 1107-1117 (2013
32. Lorente-Trigos, A., Varnat, F., Melotti, A., & Ruiz i Altaba, A. BMP signaling promotes the growth of primary human colon carcinomas in vivo. J. Mol. Cell Biol. 2, 318-332 (2010
33. Li, Y., et al. G protein-coupled estrogen receptor is involved in modulating colonic motor function via nitric oxide release in C57BL/6 female mice. Neurogastroenterol. Motil. 28, 432-442 (2016
34. Lyu, J. H., et al. RGS2 suppresses breast cancer cell growth via a MCPIP1-dependent pathway. J. Cell. Biochem. 116, 260-267 (2015
35. Hao, M. W., et al. Transcription factor EGR-1 inhibits growth of hepatocellular carcinoma and esophageal carcinoma cell lines. World J. Gastroenterol. 8, 203-207 (2002
36. Tice, D. A., Soloviev, I., & Polakis, P. Activation of the Wnt pathway interferes with serum response element-driven transcription of immediate early genes. J. Biol. Chem. 277, 6118-6123 (2002
37. Collins, F. S., & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793-795 (2015
38. Huang, M., Shen, A., Ding, J., & Geng, M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol. Sci. 35, 41-50 (2014
39. Neal, J. W., & Sledge, G. W. Decade in review-Targeted therapy: successes, toxicities and challenges in solid tumours. Nat. Rev. 11, 627-628 (2014
40. Hoelder, S., Clarke, P. A., & Workman, P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol. Oncol. 6, 155-176 (2012
41. Le Tourneau, C., et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet. Oncol. 16, 1324-1334 (2015
42. Kidd, B. A., et al. Mapping the effects of drugs on the immune system. Nat. Biotechnol. 34, 47-54 (2016
43. Iorio, F., et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl Acad. Sci. USA 107, 14621-14626 (2010
44. Iorio, F., et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740-754 (2016
45. Garnett, M. J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012
46. Yu, D. H., et al. Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-Tumor activity is enhanced by combination therapy. PLoS ONE 3, e3951 (2008
47. Venugopal, C., et al. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells. Clin. Cancer Res. 21, 5324-5337 (2015
48. Deng, L., et al. Pyrvinium targets autophagy addiction to promote cancer cell death. Cell Death Dis. 4, e614 (2013
49. Hernandez-Vargas, H., Palacios, J., & Moreno-Bueno, G. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene 26, 2902-2913 (2007
50. Niepel, M., et al. Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines. Sci. Signal. 6, ra84 (2013
51. Wei, S., et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol. Oncol. 7, 297-307 (2013
52. Chen, B., Sirota, M., Fan-Minogue, H., Hadley, D., & Butte, A. J. Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research. BMC Med. Genomics 8(Suppl 2): S5 (2015
53. Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013
54. Anders, S., & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010
55. Chen, B., et al. Relating chemical structure to cellular response: an integrative analysis of gene expression, bioactivity, and structural data across 11, 000 compounds. CPT Pharmacometrics Syst. Pharmacol. 4, 576-584 (2015
56. Holliday, D. L., & Speirs, V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 13, 215 (2011
57. Lacroix, M., & Leclercq, G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 83, 249-289 (2004
58. Chen, Y., Li, Y., Narayan, R., Subramanian, A., & Xie, X. Gene expression inference with deep learning. Bioinformatics 32, 1832-1839 2016
59. Vidovic, D., Koleti, A., & Schurer, S. C. Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action. Front. Genet. 5, 342 (2014
60. Cheng, J., et al. Evaluation of analytical methods for connectivity map data. Pac. Symp. Biocomput. 2013, 5-16, (2013
61. Duan, Q., et al. L1000CDS2: LINCS L1000 characteristic direction signatures search engine. NPJ Syst. Biol. Appl. 2, 16015 (2016
62. van Westen, G. J., Gaulton, A., & Overington, J. P. Chemical, target, and bioactive properties of allosteric modulation. PLoS Comput. Biol. 10, e1003559 (2014
63. Gao, J., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013